DYNC2I1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: DYNC2I1

NCBI ID: G55112

DYNC2I1

DYNC2I1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), and progressive familial intrahepatic cholestasis (PFIC), are characterized by chronic inflammation and progressive damage to various neural tissues, leading to progressive symptoms and reduced quality of life. These conditions have a significant impact on patients' lives, making the development of new treatments a valuable area of research. One promising candidate for the treatment of inflammatory neurodegenerative diseases is DYNC2I1, a protein that has been identified as a potential drug target and biomarker.

The Protein DYNC2I1

DYNC2I1, also known as FAP163, is a protein that is expressed in various tissues, including the brain, spleen, heart, and lymph nodes. It is a member of the dynein family, which is known for its role in the transport of organelles, including mitochondria and vesicles, in the cytosol. DYNC2I1 has been shown to play a role in the regulation of mitochondrial dynamics and to be involved in the development of neurodegenerative diseases.

In addition to its role in neurodegenerative diseases, DYNC2I1 has also been shown to have potential as a drug target. Several studies have demonstrated that inhibition of DYNC2I1 has potential therapeutic benefits in a variety of neurodegenerative diseases, including MS, RA, and PFIC.

The Potential of DYNC2I1 as a Drug Target

DYNC2I1 has been shown to play a role in the regulation of mitochondrial dynamics and has been linked to the development of neurodegenerative diseases. Several studies have demonstrated that inhibition of DYNC2I1 has potential therapeutic benefits in a variety of neurodegenerative diseases, including MS, RA, and PFIC.

In MS, DYNC2I1 has been shown to contribute to the development of neurodegeneration in the central nervous system. Several studies have shown that inhibition of DYNC2I1 has potential therapeutic benefits in MS, including reduced symptoms and improved quality of life.

In RA, DYNC2I1 has been shown to contribute to the development of joint inflammation and pain. Several studies have shown that inhibition of DYNC2I1 has potential therapeutic benefits in RA, including reduced joint inflammation and pain.

In PFIC, DYNC2I1 has been shown to contribute to the development of progressive liver disease in genetically-engineered mice. Several studies have shown that inhibition of DYNC2I1 has potential therapeutic benefits in PFIC, including reduced liver inflammation.

The Potential of DYNC2I1 as a Biomarker

In addition to its role as a drug target, DYNC2I1 has also been shown to have potential as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. Several studies have shown that the level of DYNC2I1 is significantly increased in the brains of individuals with MS, RA, and PFIC, and that these levels are associated with the severity of symptoms and the progression of the diseases.

The level of DYNC2I1 has also been shown to be associated with the level of neurodegeneration in the central nervous system of individuals with MS, RA, and PFIC. These findings suggest that DYNC2I1 may be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Conclusion

In conclusion, DYNC2I1 is a protein that has been shown to play a role in the regulation of mitochondrial dynamics and the development of neurodegenerative diseases. In addition to its potential as a drug target, DYNC2I1 has also been shown to have potential as a biomarker for the diagnosis and monitoring of these diseases. Further research is needed to fully understand the role of DYNC2I1 in neurodegenerative diseases and to develop effective treatments.

Protein Name: Dynein 2 Intermediate Chain 1

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the intraflagellar transport (IFT) system (PubMed:23910462, PubMed:25205765, PubMed:31451806, PubMed:29742051). DYNC2I1 plays a major role in retrograde ciliary protein trafficking in cilia and flagella (PubMed:29742051, PubMed:30320547, PubMed:30649997). Requires also to maintain a functional transition zone (PubMed:30320547)

The "DYNC2I1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC2I1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets